PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUSPENSION/SYRUP

Brand or Product Name
/Product name/ Suspension/Syrup … mg/5ml
/Product name/ Suspension/Syrup …mg/ml

Name and Strength of Active Substance(s)
Eg. Paracetamol 250mg/5ml
Paracetamol 120mg/5ml
Paracetamol 160mg/5ml

Product Description

[Visual description of the appearance of the product (colour, odour, viscosity, flavour)]
eg A cherry red coloured and cherry-flavoured liquid in form of a clear solution.

Pharmacodynamics

Paracetamol is a centrally acting analgesic and antipyretic with minimal anti-inflammatory properties.

Analgesic
The mechanism of analgesic action has not been fully determined. Paracetamol may act predominantly by inhibiting prostaglandin synthesis in the central nervous system (specifically cyclooxygenase (COX)-2) and, to a lesser extent, through a peripheral action by blocking pain-impulse generation.
The peripheral action may also be due to inhibition of prostaglandin synthesis or to inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation

Antipyretic
Paracetamol act centrally on the hypothalamic heat-regulating center to produce peripheral vasodilatation resulting in increase blood flow through the skin, sweating and heat loss. Paracetamol reduces fever by inhibiting the formulation and release of prostaglandins in the CNS and by inhibiting endogenous pyrogens at the hypothalamic thermoregulator center

Pharmacokinetics

Following oral administration paracetamol is rapidly absorbed. Paracetamol absorption takes place mainly in the small intestine and therefore the rate of absorption is depending on the rate of gastric emptying. It has been shown that drugs which

Updated August 2011
delay gastric emptying also delay the absorption of paracetamol whereas metoclopramide (a drug which increases the rate of gastric emptying) accelerates absorption of the analgesic through the total amount absorbed doses not increase.
The presence of food in the stomach has also been reported to reduce the rate of absorption of paracetamol. Alterations in gastric pH have no appreciable effect on paracetamol absorption. During absorption, the amount of paracetamol which is inactivated is negligible and it has been shown that paracetamol dose not affect gastric mucosal permeability and does not produce mucosal bleeding.

Peak plasma concentrations are reached 1 hour after absorption. The plasma half life is 1 to 3 hours.
Paracetamol penetrates the brain and is present in breast milk of human.
Paracetamol is metabolized by the microsomal enzyme system of the liver. This metabolism is mainly to the glucuronide and sulphate conjugates, accounting for approximately 49% and 26% of the ingested dose respectively. About 4% is excreted as free paracetamol. Other minor pathways include the production of catechol derivatives and cysteine conjugates (via glutathione). Paracetamol excretion is rapid and occurs via the urine.

**Indication**

Indicated for the relief of fever, headache and symptoms of cold and flu, toothache, discomfort of teething and fever after vaccination.

**Recommended Dosage**

It is more accurate to use the body weight of the child to calculate the correct dose in paediatrics. Calculation is based on recommended dose of 10 to 15 mg/kg/dose ORALLY every 4 to 6 hours.
(*Note: 1kg = 2.2lb)*

Doses of paracetamol for pain and fever in children, *given according to age*, are:
3 months to 1 year: 60 to 120 mg
1 to 5 years: 120 to 250 mg
6 to 12 years: 250 to 500 mg
These doses may be given every 4 to 6 hours if necessary up to a maximum of 4 doses in 24 hours.

*In younger children :
neonates 28 to 32 weeks postmenstrual age (gestational age at birth plus chronological age): 20

*Updated August 2011*
mg/kg as a single dose then 10 to 15 mg/kg every 8 to 12 hours if necessary up to a maximum of 30 mg/kg daily
neonates over 32 weeks postmenstrual age: 20 mg/kg as a single dose then 10 to 15 mg/kg every 6 to 8 hours if necessary up to a maximum of 60 mg/kg daily
1 to 3 months of age: 30 to 60 mg every 8 hours if necessary

Children with more severe symptoms:
1 to 3 months: 20 to 30 mg/kg as a single dose followed by 15 to 20 mg/kg every 6 to 8 hours if necessary up to a maximum of 60 mg/kg daily
older children: 20 to 30 mg/kg as a single dose followed by 15 to 20 mg/kg every 6 to 8 hours if necessary to a maximum of 90 mg/kg daily.

For post-immunisation pyrexia, an oral dose of 60 mg has been recommended for children 2 to 3 months of age. If necessary a second dose may be given after six hours; if the pyrexia persists after that dose, medical advice should be sought.

Mode of Administration
Oral

Contraindications
Hypersensitivity to paracetamol or any of the other ingredients/components of the product
Severe and active hepatic impairment

Warnings and Precautions
[Specific package insert requirement for paracetamol]

- Keep out of reach of children.
- Do not take if allergic to paracetamol.
- Patients should contact their health care provider if symptoms persist (if the pain lasts for more than 10 days, if there is redness or fever lasts more than 3 days).
- Paracetamol should be given with care to patients with impaired kidney or liver function.
- Large doses should be avoided in patients with hepatic impairment. Paracetamol overdose may harm the liver.

Updated August 2011
• Do not exceed recommended dose.
• Paracetamol provides symptomatic relief only, additional therapy to treat the cause of the pain or fever should be instituted when necessary.

*Effects on Ability to Drive and Use Machines*
It is unlikely to impair a patient’s ability to drive or use machinery.

*Interactions with Other Medicaments*

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.

*Statement on Usage During Pregnancy and Lactation*

*Use in pregnancy:*
• Considered to be the analgesic of choice in pregnant patients.
• Although it crosses placenta, paracetamol is considered to be safe in normal therapeutic doses for short-term use as a minor analgesic/antipyretic in pregnancy.

*Use in lactation:*
• Excreted in breast milk.
• Maternal ingestion of paracetamol in normal therapeutic doses does not appear to present a risk to the nursing infant.

*Adverse Effects / Undesirable Effects*
Adverse effects of paracetamol are rare and usually mild, although haematological reactions have been reported. Skin rashes and other hypersensitivity reactions occur occasionally.

*Overdose and Treatment*

*Symptoms:*

Toxic symptoms include vomiting, abdominal pain, hypotension and sweating. The most serious adverse effect of acute overdose of paracetamol is a dose-dependent, potentially fatal hepatic necrosis. Clinical and laboratory evidence of hepatotoxicity may be delayed for up to one week. Major manifestations of liver failure such as jaundice, hypoglycemia and metabolic acidosis may take at least 3 days to develop.
Treatment:

In cases of overdose, methods of reducing the absorption of ingested drug are important. Gastric lavage is essential even if several hours have elapsed. Prompt administration of 50g activated charcoal and 500ml iced mannitol 20% by mouth, may reduce absorption. If the history suggests that 15g Paracetamol or more has been ingested, administer one of the following antidotes:

**Acetylcysteine 20% i.v.:** Administer intravenously, 20% acetylcysteine (Parvolex, Glaxo) immediately without waiting for positive urine test or plasma level results: initial dose of 150mg/kg over 15 minutes, followed by continuous infusion of 50mg/kg in 500ml 5% glucose/dextrose over 4 hours and 100mg/kg in 1L 5% glucose/dextrose over 16 hours; or

**OR**

**Oral Methionine:** 2.5g immediately followed by three further doses of 2.5g at four hourly intervals. For a 3 year old child, 1g methionine every four hours for four doses has been used;

**OR**

**Oral Acetylcysteine 5%:** 140mg/kg as a loading dose, then 70mg/kg every 4 hours for a total of 17 maintenance doses. If more than ten hours have elapsed since the overdosage was taken, the antidote may be ineffective

**Storage Conditions**

*Store below ...°C*

**Dosage Forms and Packaging Available**

*Packaging type & pack size*

**Name and Address of Manufacturer**

*Name & full address of manufacturer*

**Name and Address of Marketing Authorization Holder**

*Name & full address of marketing authorization holder*

**Date of Revision of Package Insert**

*day/month/year*

Updated August 2011